Skip to main
ANVS

Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio (ANVS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annovis Bio Inc. is well-positioned for growth as its lead product, Buntanetap, shows potential in modifying disease progression for chronic neurodegenerative diseases like Alzheimer's and Parkinson's. Positive interim results from the Part A trial have demonstrated reduced sAPP levels, and the company plans to initiate a Phase 2 trial in the second half of 2025, indicating a robust developmental pipeline. Additionally, reaching alignment with the FDA regarding their new drug application process enhances the likelihood of successful market entry for their products, suggesting significant future revenue opportunities.

Bears say

Annovis Bio faces significant financial risks, primarily due to its limited cash runway, which raises concerns about potential dilutive capital raising activities. The company’s pipeline, focused on challenging neurodegenerative diseases such as Alzheimer's and Parkinson's, faces high uncertainty, with possible trial failures related to efficacy and safety. Additional risks include the potential lack of FDA approval for its products and anticipated challenges in market performance due to increased competition and pricing pressures, all contributing to a negative outlook for the stock.

Annovis Bio (ANVS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annovis Bio (ANVS) Forecast

Analysts have given Annovis Bio (ANVS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Annovis Bio (ANVS) has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annovis Bio (ANVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.